Acoramidis Treatment Is Effective in Patients With ATTR-CM

By CardioNerds, Kevin M. Alexander, MD - Last Updated: April 17, 2025

The CardioNerds Academy Fellows Drs. Anna Radakrishnan and Georgia Vasilakis Tsatiris conclude a 3-part discussion with Dr. Kevin M. Alexander by exploring the findings of the ATTRibute-CM clinical trial, which Dr. Alexander presented at the 2024 International Symposium on Amyloidosis. The study found that acoramidis treatment resulted in an early and profound reduction in cardiovascular hospitalizations and mortality in patients with transthyretin amyloid cardiomyopathy.

Advertisement

Advertisement
Advertisement
Advertisement